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Introduction
Enzyme-linked immunoassays (ELISAs) were developed in the late 1960s as an alternative to radiolabelling techniques for serological analyses and rapidly gained widespread use for antibody detection [1, 2] . In the field of immune-mediated diseases, the presence of autoantibodies to cytokines has attracted much debate and interest. Theoretically, neutralizing autoantibodies against cytokines may counteract physiological regulation of inflammatory responses, but possibly also serve as a physiological means to down-regulate or balance misdirected or excessive immune responses [3] . Therapeutic use of cytokines, e.g. beta interferon (IFN) in multiple sclerosis, may induce formation of neutralizing anti-cytokine (auto-) antibodies leading to resistance to therapy [4] , and possibly deficient cytokine homeostasis. In other instances, therapy targeting cytokines or cytokine-receptors can efficiently halt the progression of autoimmune or autoinflammatory diseases, as illustrated by antibodies to tumor necrosis factor (TNF) or interleukin-(IL-) 6 receptor in rheumatoid arthritis (RA), and IL-1 targeting therapies in cryopyrin associated periodic fever syndromes [5] [6] [7] . Commercially available cytokines and other sensitive molecules are often provided in the presence of bovine serum albumin (BSA) as an inert carrier or stabilizer to preserve the biological functions and to allow prolonged storage. In ELISAs, it is commonplace to include BSA as a blocker in order to prevent non-specific binding.
A large number of studies have addressed the occurrence and possible roles of autoantibodies to cytokines in different autoimmune conditions, providing evidence of their existence and describing possible associations with clinical outcomes [3] . However, the most frequently used method of detection is different ELISA variants and, as pointed out by Bendtzen et al, there are several points that need to be addressed when developing an anti-cytokine ELISA [8, 9] ; these precautions apply also for other immunosorbent assays. Apart from non-specific binding to the antigen or to the plastic surface, immobilization of the antigen to the plastic surface may cause loss of its native three-dimensional structure and thereby exposure of neoepitopes. Furthermore, the presence of soluble cytokine receptors needs be taken into account when interpreting the results of anti-cytokine antibody assays [10] .
In a previous study we described an inverse correlation between autoantibodies to TNF and disease activity in patients with systemic lupus erythematosus (SLE) [11] . Also, we reported decreased levels of autoantibodies to IL-1 and TNF in RA patients, which also possibly associated with a worse disease course during three years [12] . The same cytokines were used to block anti-reactivity by pre-adsorption of the patient sera, whereas (very unfortunately) the non-relevant cytokine preparation used as control in the blocking experiments did not contain BSA! When we became aware of this, it urged us to perform a systematic review of our previous results.
Materials and Methods

Subjects
Between January 1996 and March 1998, 320 patients with early RA were enrolled in a prospective observational cohort study in southeastern Sweden named 'TIRA-1' (Swedish acronym for "early interventions in rheumatoid arthritis") [13] . The patients either fulfilled at least 4/7 of the 1987 American College of Rheumatology (ACR) classification criteria for RA, and the remainder presented with morning stiffness ≥ 60 min, symmetrical arthritis and small joint arthritis. Baseline sera from 189 TIRA-1 patients were available for the present study and characteristics of the patients are given in Table 1 . Symptom duration was at least 6 weeks but less than 1 year, and 97% (184/189) fulfilled ≥4/7 of the ACR criteria and 63%
(119/189) were RF-positive as tested on a routine basis by means of latex particle agglutination. The patients were monitored regularly during three years regarding disease activity, pharmacotherapy and functional status. Disease activity was assessed by the 28-joint disease activity score (DAS28) [14] . The control population comprised 186 healthy blood donors (90 females, 96 males, mean age 41 years, range 20-66).
Antibody detection
Serum samples from patients and controls were taken at inclusion and were kept frozen (-72° C) until analysis. The ELISAs were performed with the antigen being either (1) 
Inhibition assay
Altogether, 24 sera, originated from TIRA-1 patients and controls with high ODs achieved in anti-TNF/BSA assay, were used in an inhibition assay. All sera were pre-incubated for 1 h in room temperature with PBS containing either 2% BSA or HSA. Each sample was then diluted to a final concentration of 1:100, applied to plates coated with TNF/BSA and treated as described above.
Statistics
Figures were prepared in GraphPad Prism (version 4.0; GraphPad Software Inc., San Diego, CA, USA). Correlation analyses were performed using Spearman's rank correlation (GraphPad) and differences between groups were calculated with the Mann-Whitney U test (GraphPad).
Ethics
All patients gave their written informed consent and the local ethics committee in Linköping approved the study protocol.
Results
Using a cut-off at 0.1 net OD, 25% (47/189) of TIRA-1 patients and 43% of the controls were anti-TNF/BSA positive; and the anti-TNF/BSA antibody levels were not significantly different between the groups (p = 0.24). Data revealed no significant difference in antibody reactivity between women and men.
Likewise, as illustrated in Figure 1 , antibodies to BSA were common in both groups; 50%
(95/189) of RA patients and 62% (116/186) of controls were anti-BSA positive using a cut-off at 0.1 net OD. No significant difference in anti-BSA antibody levels were found between the groups (p = 0.11) and no difference in antibody reactivity between women and men was found. However, as shown in Figure 2 , we found a solid correlation between anti-TNF/BSA and anti-BSA levels (Spearman; r = 0.811, p < 0.001). Very low levels of anti-TNF/HSA were found in individual RA sera but without correlation to anti-BSA (Spearman; r = -0.087, p = 0.27). 
Discussion
The first descriptions of antibodies against cytokines were made in the early 80s when the presence of antibodies to human interferon- (IFN) was reported in a patient with SLE [15] and in a patient suffering from Varicella-zoster infection [16] . Reports on the presence of autoantibodies to TNF, interleukins, interferons, growth and colony-stimulating factors (CSF) in autoimmune diseases, infections, graft-versus-host, malignancies and apparently healthy individuals followed [17] [18] [19] [20] [21] [22] . Some studies revealed associations between levels of specific anti-cytokine antibodies and certain clinical manifestations. For instance, anti-IL-1 has been suggested to prevent bone erosions in RA [23, 24] , anti-IL-6 was found in patients with severe alcoholic cirrhosis [25] , autoantibodies to granulocyte CSF were present in neutropenic SLE patients [26] , and the appearance of anti-IFN was observed in relation to disease remission in Guillain-Barré syndrome [27] . Few of these studies have been confirmed by other research groups and far from all checked for cytokine-neutralizing capacity of the detected anticytokine antibody. In addition, the observations were made with several different assays, e.g.
ELISAs, immunoblotting and radioimmunoassays (RIAs), all using purified cytokines as source of antigen. The presence, or absence, of BSA in the used cytokine preparations was rarely stated.
Bendtzen and co-workers have studied anti-cytokine antibodies in health and disease for many years [28] . Initially, they used immunoblotting and ELISAs [18] but abandoned these methods for radioiodinated-based methods due to lack of sensitivity [9] . Whether the anticytokine antibodies are friends, foes or just innocent bystanders has long been a subject of debate. Therapy-induced antibodies to cytokines were generally thought to inhibit cytokine functions, and thus eventually resulting in various degrees of 'cytokine deficiency'. However, when the presence of various naturally occurring anti-cytokine antibodies also became apparent [21, 22, 29, 30] , it was proposed that some of these antibodies could serve as specific carriers to deliver cytokines to target cells. Hypothetically, this physiological carrier function could also delay cytokine elimination from the circulation and protect it from proteolytic degradation [28] . Other potential in-vivo functions of anti-cytokine antibodies include roles as: (1) Our interest in anti-cytokine antibodies arose in relation to SLE, a disease characterized by deviating cytokine patterns and multiple autoantibodies to antigens in cell nuclei, cytoplasm and cytoplasmic organelles, cell surface antigens and circulating plasma proteins. We hypothesized that neutralizing antibodies to cytokines essential for the induction of CRP (i.e.
IL-6, IL-1 and TNF) could explain why SLE patients, in spite of high disease activity and elevated IL-6, often display a remarkably poor CRP response. In-house ELISAs were developed in accordance with the description by Elkarim et al [27] and the antigen specificities of our assays were validated as suggested by Bendtzen [8] . Contrary to our expectations, we found no evidence of raised autoantibody levels to CRP-inducing cytokines as compared to healthy controls. Neither did we find any correlations between CRP levels and any of the tested anti-cytokine autoantibodies [11] . However, anti-TNF antibody levels were significantly lower in patient sera from active disease as compared to remission samples, and anti-TNF levels were strongly inversely associated with disease activity in certain patients [11] . At first, the efforts to prove the antigen specificities of our different anti-cytokine ELISAs were apparently successful, since pre-incubation of the sera with "relevant" cytokine abolished antibody reactivity, whereas pre-incubation of "irrelevant" cytokine (consistently IFN) did not. In retrospect, however, we have become painfully aware of the fact that all of the relevant cytokines used to coat microtitre plates and pre-adsorb serum samples, actually contained considerable amounts of BSA as carrier protein, whereas the "irrelevant" cytokine had HSA as carrier protein! in subjects with IgA-deficiency, and hypothesized that this could be explained to systemic immunization to dietary proteins due to lack of mucosal IgA-mediated immune exclusion [32] . However, also in populations-based samples, the occurrence of IgG antibodies to BSA is a common finding although levels seem to decline with age [33, 34] . In human disease, anti-BSA has attracted most interest regarding insulin dependent diabetes mellitus (IDDM), where increased levels of anti-BSA antibodies as well as cross reactivity between a BSA peptide sequence and a pancreatic -cell surface protein has been suggested [35, 36] and the potential role of BSA and other cow's milk proteins in the development of IDDM is still a matter of considerable interest [37, 38] . In a study by Mogues et al, a sensitive quantitative anti-BSA antibody assay was developed, and a proper cut-off level was carefully defined [39] . By this method, they found IgG-class anti-BSA antibodies in sera of slightly above 50% among lung cancer patients undergoing surgery. The levels and frequency of anti-BSA antibodies in healthy blood donors were similar. In patients exposed to BSA in an intra-thoracic surgical sealant after pulmectomy, the antibody levels increased steeply and the frequency of positive anti-BSA tests rose to 96% [39] . In diseases characterized by a compromised gastrointestinal barrier, such as Crohn's and celiac disease, levels of anti-BSA antibodies seem to be increased [40, 41] , and in SLE, anti-BSA levels have both been found to be elevated and to correlate to an increased risk of cardiovascular disease [42] . Rosenau & Schur recently reported that the serum levels of anti-TNF autoantibodies in RA did not correlate with disease activity (CRP, erythrocyte sedimentation rate), but concluded that anti-TNF autoantibodies may reduce disease activity, since RA patients with high serum levels did not develop joint erosions [43] . In a meeting abstract 2004, we presented a similar conclusion regarding disease-modifying properties of anti-TNF and anti-IL1 autoantibodies in RA since patients with subnormal levels (as compared to healthy controls) showed a tendency to higher disease activity over time as compared to patients with normal antibody levels [12] . Rosenau & Schur used buffer containing 2% BSA to block non-specific antibody binding to TNF-coated microtitre plates, but in contrast to us they also took the precaution to dilute serum samples with the same 'blocking buffer' [43] . However, apart from interference by antibodies to dietary antigens (such as BSA and other milk proteins commonly used as blockers of non-specific reactions), it is well known that rheumatoid factors can meddle with the results of immunoassays. This may be due to reaction with secondary detection antibodies [44] , but also due to interaction with soluble immune complexes in the patient serum, or by reaction with serum antibodies immobilized on the microtitre plate. Furthermore, even when taking the precaution of neutralizing serum antibodies with the "blocking agent" (such as BSA), rheumatoid factor of any isotype may interact both with the "iatrogenic" immune complexes in serum and with antibodies bound to the microtitre plate and thereby producing erroneous results. However, although RF may hypothetically obscure the results of any ELISA, this did not appear to be a major risk in our study, since we found no differences regarding anti-BSA antibody results comparing seropositive and seronegative RA patients.
The results of the present study clearly demonstrate that our previously published results on anti-cytokine antibodies in SLE and RA patients [11, 12] 
